Aprotinin versus lysine analogues: The debate continues

Annals of Thoracic Surgery

Volumn 65, Issue 4 SUPPL., 1998, Pages

  Royston, David ^a  

^a HAREFIELD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ANTIPLASMIN; AMINOCAPROIC ACID; APROTININ; CREATININE; LYSINE DERIVATIVE; PLACEBO; SERINE PROTEINASE INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; TRANEXAMIC ACID;

ACUTE KIDNEY FAILURE; ANTIINFLAMMATORY ACTIVITY; BLOOD CLOT LYSIS; BLOOD TRANSFUSION; BLOOD VESSEL REACTIVITY; BLOOD VESSEL TONE; CARDIOPULMONARY ARREST; CATHETER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; FIBRINOLYSIS; HEMOSTASIS; HUMAN; LIPID PEROXIDATION; LUNG ARTERY PRESSURE; NEUTROPHIL; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; PROTEINURIA; REVIEW; THROMBOSIS;

EID: 0031960064     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-4975(98)00071-X     Document Type: Article

References (94)

1. 2-antiplasmin supplementation inhibits tissue plasminogen activator-induced fibrinogenolysis and bleeding with little effect on thrombolysis. J Clin Invest. 91:1993;1343-1350.
2. Fears R, Greenwood J, Hearn J, Howard BS, Morrow G, Standring R. Inhibition of the fibrinolytic and fibrinogenolytic activity of plasminogen activators in vitro by the antidotes epsilon-aminocaproic acid, AMCHA and aprotinin. Fibrinolysis. 6:1992;79-86.
3. Garabedian HD, Gold HK, Leinbach RC, et al. Bleeding time prolongation and bleeding during infusion of recombinant tissue-type plasminogen activator in dogs potentiation by aspirin and reversal with aprotinin . J Am Coll Cardiol. 17:1991;1213-1222.
4. De Bono DP, Pringle S, Underwood I. Differential effects of aprotinin and AMCHA on cerebral bleeding and cutaneous bleeding time during rt-PA infusion. Thromb Res. 61:1991;159-163.
5. Dietrich W, Spannagl M, Jochum M. Influence of high-dose aprotinin treatment on blood loss and coagulation patterns in patients undergoing myocardial revascularisation. Anesthesiology. 73:1990;1119-1126.
6. Green D, Ts'ao CH, Cerullo L, Cohen I, Ruo TI, Atkinson AJ Jr. Clinical and laboratory investigation of the effects of epsilon-aminocaproic acid on hemostasis. J Lab Clin Med. 105:1985;321-327.
7. Glick R, Green D, Ts'ao C, Witt WA, Yu AT, Raimondi AJ. High dose epsilon-aminocaproic acid prolongs the bleeding time and increases rebleeding and intraoperative hemorrhage in patients with subarachnoid hemorrhage. Neurosurgery. 9:1981;398-401.
8. Lemmer JH Jr, Stanford W, Bonney SL, et al. Aprotinin for coronary bypass operations: efficacy, safety, and influence on early saphenous vein graft patency. A multicenter randomized, double-blind, placebo-controlled study. J Thorac Cardiovasc Surg. 107:1994;543-551.
9. Levy J, Pifarré R, Schaff H, et al. A multicenter double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients having repeat coronary artery bypass grafting. Circulation. 92:1995;2236-2244.
10. Horrow JC, Van Riper DF, Strong MD, Brodsky I, Parmet JL. Hemostatic effects of AMCHA and desmopressin during cardiac surgery. Circulation. 84:1991;2063-2070.
11. Horrow JC, Van Riper DF, Strong MD, Grunewald KE, Parmet JL. The dose-response relationship of AMCHA. Anesthesiology. 82:1995;383-392.
12. Øvrum E, Åm Holen E, Abdelnoor M, Oystese R, Ringdal ML. Tranexamic acid (Cyklokapron) is not necessary to reduce blood loss after coronary artery bypass operations. J Thorac Cardiovasc Surg. 105:1993;78-83.
13. Coffey A, Pittmam J, Halbrook H, Fehrenbacher J, Beckman D, Hormuth D. The use of AMCHA to reduce postoperative bleeding following cardiac surgery a double-blind randomized trial . Am Surg. 61:1995;566-568.
14. Menichetti A, Tritapepe L, Ruvolo G, et al. Changes in coagulation patterns, blood loss and blood use after CPB aprotinin vs AMCHA vs epsilon-aminocaproic acid . J Cardiovasc Surg (Torino). 37:1996;401-407.
15. Karski JM, Teasdale SJ, Norman PH, Carroll JA, Weisel RD, Glynn MF. Prevention of postbypass bleeding with AMCHA and epsilon-aminocaproic acid. J Cardiothorac Vasc Anesth. 7:1993;431-435.
16. Karski JM, Teasdale SJ, Norman P, et al. Prevention of bleeding after CPB with high-dose AMCHA double-blind, randomized clinical trial . J Thorac Cardiovasc Surg. 110:1995;835-842.
17. Katsaros D, Petricevic M, Snow NJ, Woodhall DD, Van Bergen R. Tranexamic acid reduces postbypass blood use a double-blinded, prospective, randomized study of 210 patients . Ann Thorac Surg. 61:1996;1131-1135.
18. Nakashima A, Matsuzaki K, Fukumura F, et al. Tranexamic acid reduces blood loss after CPB. ASAIO J. 39:1993;M185-M189.
19. Rousou JA, Engelman RM, Flack JE, Deaton DW, Owen SG. Tranexamic acid significantly reduces blood loss associated with coronary revascularization. Ann Thorac Surg. 59:1995;671-675.
20. Yau TM, Carson S, Weisel RD, et al. The effect of warm heart surgery on postoperative bleeding. J Thorac Cardiovasc Surg. 103:1992;1155-1162.
21. Daily PO, Lamphere JA, Dembitsky WP, Adamson RM, Dans NF. Effect of prophylactic epsilon-aminocaproic acid on blood loss and transfusion requirements in patients undergoing first-time coronary artery bypass grafting a randomized, prospective, double-blind study . J Thorac Cardiovasc Surg. 108:1994;99-106.
22. Arom KV, Emery RW. Decreased postoperative drainage with addition of ε-aminocaproic acid before CPB. Ann Thorac Surg. 57:1994;1108-1112.
23. Fritz H, Wunderer G. Biochemistry and applications of aprotinin, the kallikrein inhibitor from bovine organs. Arzneimittelforschung. 33:1983;479-494.
24. Allen S, Anastasiou N, Royston D, Paniagua R, Yacoub M. Effect of aprotinin on vascular reactivity of coronary artery bypass grafts. J Thorac Cardiovasc Surg. 113:1997;319-326.
25. Blauhut B, Gross C, Necek S, Doran J, Späth P, Lundsgaard-Anderson P. Effects of high-dose aprotinin on blood loss, platelet function, fibrinolysis, complement, and renal function after CPB. J Thorac Cardiovasc Surg. 101:1991;958-967.
26. Hill GE, Alonso A, Spurzem JR, Stammers AH, Robbins RA. Aprotinin and methylprednisolone equally blunt CPB-induced inflammation in humans. J Thorac Cardiovasc Surg. 110:1995;1658-1662.
27. Wang JH, Redmond HP, Watson RW, et al. Mechanisms involved in the induction of human endothelial cell necrosis. Cell Immunol. 168:1996;91-99.
28. Liu B, Belboul A, Al-Khaja N, et al. Effect of high-dose aprotinin on blood cell filterability in association with CPB. Coronary Artery Dis. 3:1992;129-132.
29. Royston D, Bidstrup B, Fleming J, Taylor K. Platelet preservation reduces production of lipid peroxidation products during CPB in humans. Am Rev Respir Dis. 135:1987;A135.
30. Van Oeveren W, Jansen NJ, Bidstrup BP, et al. Effects of aprotinin on hemostatic mechanisms during CPB. Ann Thorac Surg. 44:1987;640-645.
31. Marx G, Pokar H, Reuter H, Doering V, Tilsner V. The effects of aprotinin on hemostatic function during cardiac surgery. J Cardiothorac Vasc Anesth. 5:1991;467-474.
32. Dietrich W, Mossinger H, Spannagl M, et al. Hemostatic activation during CPB with different aprotinin dosages in pediatric patients having cardiac operations. J Thorac Cardiovasc Surg. 105:1993;712-720.
33. Mikawa K, Akamatsu H, Maekawa N, Nishina K, Obara H, Niwa Y. Acceleration of phagocytosis in human neutrophils incubated with gabexate mesilate. J Int Med Res. 22:1994;292-295.
34. Lord RA, Roath OS, Thompson JF, Chant AD, Francis JL. Effect of aprotinin on neutrophil function after major vascular surgery. Br J Surg. 79:1992;517-521.
35. Nishijima J, Hiraoka N, Murata A, et al. Protease inhibitors (gebexate mesylate and ulinastatin) stimulate intracellular chemiluminescence in human neutrophils. J Leukoc Biol. 52:1992;262-268.
36. 2) and hydroxyl radical production by human polymorphonuclear leukocytes. Hepatogastroenterology. 39:1992;59-61.
37. Gurevitch J, Barak J, Hochhauser E, Paz Y, Yakirevich V. Aprotinin improves myocardial recovery after ischemia and reperfusion effects of the drug on isolated rat hearts . J Thorac Cardiovasc Surg. 108:1994;109-118.
38. Trofimov GA, Ardashev VN, Serova LS, et al. [Heart rupture in the acute period of myocardial infarction prognostication and ways of prevention] . Klin Med (Mosk). 72:1994;22-25.
39. Ceceña-Seldner F, Villareal B. Effect of kallikrein inhibitor aprotinin on myocardial ischemia and necrosis in man. Angiology. 31:1980;488-496.
40. Tweddell JS, Berger S, Frommelt PC, et al. Aprotinin improves outcome of single-ventricle palliation. Ann Thorac Surg. 62:1996;1329-1335.
41. Prendergast TW, Furukawa S, Beyer A Jr, Eisen HJ, McClurken JB, Jeevanandam V. Defining the role of aprotinin in heart transplantation. Ann Thorac Surg. 62:1996;670-674.
42. Goldstein DJ, Seldomridge JA, Chen JM, et al. Use of aprotinin in LVAD recipients reduces blood loss, blood use, and perioperative mortality. Ann Thorac Surg. 59:1995;1063-1067.
43. Cosgrove D, Heric B, Lytle BW, et al. Aprotinin therapy for reoperative myocardial revascularization a placebo-controlled study . Ann Thorac Surg. 54:1992;1031-1036.
44. Tsementzis SA, Honan WP, Nightingale S, Hitchcock ER, Meyer CH. Fibrinolytic activity after subarachnoid haemorrhage and the effect of AMCHA. Acta Neurochir (Wien). 103:1990;116-121.
45. Tsementzis SA, Hitchcock ER, Meyer CH. Benefits and risks of antifibrinolytic therapy in the management of ruptured intracranial aneurysms a double-blind placebo-controlled study . Acta Neurochir (Wien). 102:1990;1-10.
46. Anonymous. Protease inhibitors for delayed cerebral ischaemia after subarachnoid haemorrhage? [Editorial]. Lancet. 339:1992;1199-1200.
47. Yanamoto H, Kikuchi H, Sato M, Shimizu Y, Yoneda S, Okamoto S. Therapeutic trial of cerebral vasospasm with the serine protease inhibitor, FUT-175, administered in the acute stage after subarachnoid hemorrhage. Neurosurgery. 30:1992;358-363.
48. Yanamoto H, Kikuchi H, Okamoto S, Nozaki K. Preventive effect of synthetic serine protease inhibitor, FUT-175, on cerebral vasospasm in rabbits. Neurosurgery. 30:1992;351-356.
49. Bidstrup BP, Harrison J, Royston D, Taylor KM, Treasure T. Aprotinin therapy in cardiac operations a report on use in 41 cardiac centers in the United Kingdom . Ann Thorac Surg. 55:1993;971-976.
50. Roach G, Kanchuger M, Mangano C, et al. Adverse cerebral outcomes after coronary bypass surgery. N Engl J Med. 335:1996;1857-1863.
51. Lytle B, Loop F, Cosgrove D. Coronary reoperations results and determinants of early and late survival . J Thorac Cardiovasc Surg. 93:1987;874-895.
52. Jones E, Weintraub W, Craver J. Coronary bypass surgery is the operation different today? J Thorac Cardiovasc Surg. 101:1991;108-115.
53. Smith PK, Muhlbaier LH. Aprotinin safe and effective only with the full-dose regimen [Editorial] . Ann Thorac Surg. 62:1996;1575-1577.
54. Kamiya T, Katayama Y, Kashiwagi F, Terashi A. The role of bradykinin in mediating ischemic brain edema in rats. Stroke. 24:1993;571-575.
55. Aoki M, Jonas RA, Nomura F, et al. Effects of aprotinin on acute recovery of cerebral metabolism in piglets after hypothermic circulatory arrest. Ann Thorac Surg. 58:1994;146-153.
56. Hammermeister KE, Burchfiel C, Johnson R, Grover FL. Identification of patients at greatest risk for developing major complications at cardiac surgery [Published erratum appears in Circulation 1991;84:446]. Circulation. 82:(Suppl 4):1990;380-389.
57. Lemmer JH Jr, Stanford W, Bonney SL, et al. Aprotinin for coronary artery bypass grafting effect on postoperative renal function . Ann Thorac Surg. 59:1995;132-136.
58. Dietze G, Wicklymayr M, Mayer L. Evidence for a participation of the kallikrein-kinin system in the regulation of muscle metabolism during hypoxia. Hoppe Seylers Z Physiol Chem. 358:1977;633-638.
59. O'Connor C, McCarthy R, Barnes S, Tuman K. The effect of renal failure on plasma aprotinin levels during cardiac surgery. Anesthesiology. 87:1997;A87.
60. Biswas C, Reid-Milligan D, Agte S, Kemward D, Tillex P. Acute renal failure and myopathy after treatment with aminocaproic acid. Br Med J. 281:1980;115-116.
61. Cooksey MW, Knapp MS. Aminocaproic acid and "proteinuria" Br Med J. 1:1968;769.
62. Ratnoff OD. Epsilon-aminocaproic acid - a dangerous weapon. N Engl J Med. 280:1969;1124-1125.
63. Garwood S, Mathew J, Barash P, Hines R. Reduced blood loss at the expense of renal function is epsilon-aminocaproic acid a blow to the kidney? Anesthesiology. 87:1997;A67.
64. Feindt PR, Walcher S, Volkmer I, et al. Effects of high-dose aprotinin on renal function in aortocoronary bypass grafting. Ann Thorac Surg. 60:1995;1076-1080.
65. Kazanbiev NK, Akhmedova DA, Gasanova RG, Bagamedov MM, Sfiev AA. Anaphylactic shock in response to the administration of epsilon-aminocaproic acid. Klin Med (Mosk). 65:1987;140-141.
66. Yien HW, Hseu SS, Chan KH, Lee TY. Suspected anaphylactoid shock to aminocaproic acid (plaslloid) during operation. Chung Hua I Hsueh Tsa Chih (Taipei). 50:1992;415-419.
67. Dietrich W, Barankay A, Hahnel C, Richter JA. High-dose aprotinin in cardiac surgery three years' experience in 1,784 patients . J Cardiothorac Vasc Anesth. 6:1992;324-327.
68. Paroli A, Antona C, Gerometta P, et al. The effect of high-dose aprotinin and other factors on bleeding and revisions for bleeding in adult coronary and valve operations an analysis of 2190 patients during a five-year period (1987-1991) . Eur J Cardiothorac Surg. 9:1995;77-82.
69. Levy JH. Anaphylactic/anaphylactoid reactions during cardiac surgery. J Clin Anesth. 1:1989;426-430.
70. Laxenaire MC, Charpentier C, Feldman L. Anaphylactoid reactions to colloid plasma substitutes: incidence, risk factors, mechanisms. A French multicenter prospective study. Ann Fr Anesth Reanim. 13:1994;301-310.
71. Dewachter P, Mouton C, Masson C, Gueant JL, Haberer JP. Anaphylactic reaction to aprotinin during cardiac surgery [Letter]. Anaesthesia. 48:1993;1110-1111.
72. Diefenbach C, Abel M, Limpers B, et al. Fatal anaphylactic shock after aprotinin reexposure in cardiac surgery. Anesth Analg. 80:1995;830-831.
73. Ceriana P, Maurelli M, Locatelli A, Bianchi T, Maccario R, De Amici M. Anaphylactic reaction to aprotinin [Letter]. J Cardiothorac Vasc Anesth. 9:1995;477-478.
74. Schulze K, Graeter T, Schaps D, Hausen B. Severe anaphylactic shock due to repeated application of aprotinin in patients following intrathoracic aortic replacement. Eur J Cardiothorac Surg. 7:1993;495-496.
75. Dietrich W, Spath P, Ebell A, Richter JA. Prevalence of anaphylactic reactions to aprotinin analysis of two hundred forty-eight reexposures to aprotinin in heart operations . J Thorac Cardiovasc Surg. 113:1997;194-201.
76. Scott RM, Garrido E. Spontaneous thrombosis of an intracranial aneurysm during treatment with epsilon-aminocaproic acid. Surg Neurol. 7:1977;21-23.
77. Fodstad H, Liliequist B. Spontaneous thrombosis of ruptured intracranial aneurysms during treatment with AMCHA (AMCA) report of three cases . Acta Neurochir (Wien). 49:1979;129-144.
78. Hoffman EP, Koo AH. Cerebral thrombosis associated with EACA therapy. Radiology. 131:1979;687-689.
79. Tubbs RR, Benjamin SP, Dohn DE. Recurrent subarachnoid hemorrhage associated with aminocaproic acid therapy and acute renal artery thrombosis. Case report. J Neurosurg. 51:1979;94-97.
80. Tanghetti B, Capra R, Marini G. Spontaneous thrombosis of ruptured intracranial aneurysm during treatment with tranexamic acid. Case report. J Neurosurg Sci. 29:1985;105-108.
81. Brooke CP, Spiers EM, Omura EF. Noninflammatory bullae associated with epsilon-aminocaproic acid infusion. J Am Acad Dermatol. 27:1992;880-882.
82. Tytgat G, Collen D, Verstraete M. Metabolism of fibrinogen in cirrhosis of the liver. J Clin Invest. 50:1971;1690-1701.
83. Dentz ME, Slaughter TF, Mark JB. Early thrombus formation on heparin-bonded pulmonary artery catheters in patients receiving epsilon-aminocaproic acid. Anesthesiology. 82:1995;583-586.
84. Hocker JR, Saving KL. Fatal aortic thrombosis in a neonate during infusion of epsilon-aminocaproic acid. J Pediatr Surg. 30:1995;1490-1492.
85. Prah GN, Lisman SR, Maslow AD, Freeman RB, Rohrer RJ. Transesophageal echocardiography reveals an unusual cause of hemodynamic collapse during orthotopic liver transplantation - two case reports. Transplantation. 59:1995;921-925.
86. Umbrain V, Christiaens F, Camu F. Intraoperative coronary thrombosis can aprotinin and protamine be incriminated? J Cardiothorac Vasc Anesth. 8:1994;198-201.
87. Bohrer H, Fleischer F, Lang J, Vahl C. Early formation of thrombi on pulmonary artery catheters in cardiac surgical patients receiving high-dose aprotinin. J Cardiothorac Anesth. 4:1990;222-225.
88. Gitter R, Alivizators P, Capehart J, Ramsay M, Jett GK. Aprotinin and aortic cannula thrombosis. J Thorac Cardiovasc Surg. 112:1996;537-538.
89. Hayhurst MD. Extensive thrombosis following central venous catheterization - a relationship to antifibrinolytic therapy? [Letter]. S Afr Med J. 63:1983;797.
90. Youngberg JA. Aprotinin and thrombus formation on pulmonary artery catheters a piece of the coagulation puzzle [Editorial] . J Cardiothorac Anesth. 4:1990;155-158.
91. MacIomhair M, Lavelle SM. Thrombus weight as a measure of hypercoagulability induced by drugs. Thromb Haemost. 42:1979;1018-1021.
92. Kalangos A, Tayyareci G, Pretre R, Di Dio P, Sezerman O. Influence of aprotinin on early graft thrombosis in patients undergoing myocardial revascularization. Eur J Cardiothorac Surg. 8:1994;651-656.
93. Havel M, Grabenwoger F, Schneider J, et al. Aprotinin does not decrease early graft patency after coronary artery bypass grafting despite reducing postoperative bleeding and use of donated blood. J Thorac Cardiovasc Surg. 107:1994;807-810.
94. Lass M, Welz A, Kochs M, Mayer G, Schwandt M, Hannekum A. Aprotinin in elective primary bypass surgery graft patency and clinical efficacy . Eur J Cardiothorac Surg. 9:1995;206-210.